Meeting News CoverageVideo

VIDEO: Ado-trastuzumab emtansine plus pertuzumab effective for HER-2–positive breast cancer

NEW ORLEANS — Lajos Pusztai, MD, Dphil, medical oncologist at Yale Cancer Center, discusses the impact of the I-SPY 2 trial presented at the American Association for Cancer Research Annual Meeting.

Results showed neoadjuvant treatment with ado-trastuzumab emtansine (Kadcyla, Genentech) plus pertuzumab (Perjeta, Genentech) induced a higher rate of pathologic complete response than the current standard of care, which consists of paclitaxel plus trastuzumab (Herceptin, Genentech).

The therapy also appeared well tolerated.

“The next important question in this study will be about how those who do not achieve pathologic complete response can be salvaged by using adjuvant therapy from the remainder of conductive drugs that they haven’t received in the neoadjuvant setting,” Pusztai told HemOnc Today.

NEW ORLEANS — Lajos Pusztai, MD, Dphil, medical oncologist at Yale Cancer Center, discusses the impact of the I-SPY 2 trial presented at the American Association for Cancer Research Annual Meeting.

Results showed neoadjuvant treatment with ado-trastuzumab emtansine (Kadcyla, Genentech) plus pertuzumab (Perjeta, Genentech) induced a higher rate of pathologic complete response than the current standard of care, which consists of paclitaxel plus trastuzumab (Herceptin, Genentech).

The therapy also appeared well tolerated.

“The next important question in this study will be about how those who do not achieve pathologic complete response can be salvaged by using adjuvant therapy from the remainder of conductive drugs that they haven’t received in the neoadjuvant setting,” Pusztai told HemOnc Today.

    See more from American Association for Cancer Research Annual Meeting